Lung Cancer

Dave Nitsche, a nonsmoker and endurance athlete, pushes back against stigma and stays active while advocating for lung cancer screening.

October brought updates in the lung cancer field, ranging from notable trial results to patient perspectives on navigating treatment and survivorship.

More than a quarter of tested patients with non-small cell lung cancer responded to Amtagvi monotherapy.

LiveLung invites the CSRA’s lung cancer community to its educational meeting.

LiveLung invites the Charlotte lung cancer community to its monthly educational meeting.

LiveLung invites the community to its monthly Small Cell Lung Cancer (SCLC) virtual educational meeting.

A cancer survivor explains how humor helped her during her cancer journey.

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

LiveLung invites the Wilmington community to its monthly educational meeting.

My first oncologist got me started with positivity in my cancer journey, which I was thankfully able to internalize.

Alecensa cut the risk of death by 22% versus Xalkori, with median overall survival reaching 81.1 months versus 54.2 months in advanced ALK-positive lung cancer.

The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

LiveLung, a nonprofit organization, invites the CSRA’s lung cancer community to its educational meeting.

Brittney Nichols discussed the emotional and physical side effects of lung cancer treatment, as well as feelings of isolation in newly diagnosed patients.

Brittney Nichols highlights the need for early detection and stresses that lung cancer is not only caused by smoking; anyone can develop the disease.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.